Article Menu

Export Article

More by Authors Links

Article Data

  • Views 3516
  • Dowloads 259

Editorials

Open Access

Vulvar lichen sclerosus oncologic risk: italian interdisciplinary Society of Vulvology (SIIV) Position Paper

  • Monica Corazza1
  • Camilla Salvini2
  • Angelina De Magnis3
  • Pina Belfiore4
  • Carmine Carriero5
  • Stefano Crippa6
  • Luciano Mariani7,‡
  • Leonardo Micheletti8
  • Eleonora P Preti9
  • Gianluigi Radici8
  • Gianluigi Taddei10
  • Giulio Tosti11
  • Annarosa Virgili1
  • Mario Preti8,*,

1Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy

2Dermatology Unit, Department of Health Sciences, University of Florence, 50122 Florence, Italy

3Department of Gynecology and Obstetrics, University of Florence, 50122 Florence, Italy

4Section of Gynecology and Obstetrics, Department of Health, University of Palermo, 90121 Palermo, Italy

5Department Interdisciplinary Medicine, Unit of Obstetrics and Gynecology, University of Bari ``Aldo Moro", 70121 Bari, Italy

6Cellular Pathology, Luton & Dunstable University Hospital, Bedforshire Hospitals NHS Foundation Trust, LU4 0DZ Luton, UK

7HPV-Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy

8Department of Surgical Sciences, University of Turin, 10126 Turin, Italy

9Preventive Gynecology Unit, European Institute of Oncology IRCCS, 20139 Milan, Italy

10Department of Science for Woman and Child Health, University of Florence, 50122 Florence, Italy

11Division of Melanoma Surgery, Sarcoma and Rare Tumors, European Institute of Oncology IRCCS, 20139 Milan, Italy

DOI: 10.22514/ejgo.2022.006 Vol.43,Issue 3,June 2022 pp.1-3

Submitted: 31 March 2022 Accepted: 13 April 2022

Published: 15 June 2022

*Corresponding Author(s): Mario Preti E-mail: mario.preti@unito.it

‡ Dead author.

PDF (269.06 kB) View Full-text

Keywords

lichen sclerosus; vulvar cancer; vulvar intraepithelial neoplasia


Cite and Share

Monica Corazza,Camilla Salvini,Angelina De Magnis,Pina Belfiore,Carmine Carriero,Stefano Crippa,Luciano Mariani,Leonardo Micheletti,Eleonora P Preti,Gianluigi Radici,Gianluigi Taddei,Giulio Tosti,Annarosa Virgili,Mario Preti. Vulvar lichen sclerosus oncologic risk: italian interdisciplinary Society of Vulvology (SIIV) Position Paper. European Journal of Gynaecological Oncology. 2022. 43(3);1-3.

URL:

https://www.ejgo.net/articles/10.22514/ejgo.2022.006

References

[1] Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. The British Journal of Dermatology. 2018; 178: 839–853.

[2] Niamh L, Naveen S, Hazel B. Diagnosis of Vulval Inflammatory Dermatoses: a Pathological Study with Clinical Correlation. International Journal of Gynecological Pathology. 2009; 28: 554–558.

[3] Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosus: A Prospective Cohort Study of 507 Women. JAMA Dermatology. 2015; 151: 1061–1067.

[4] Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. Journal of the American Academy of Dermatology. 2011; 64: e99–e104.

[5] Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. Journal of the American Academy of Dermatology. 2014; 71: 84–91.

[6] Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. British Journal of Dermatology. 2014; 171: 388–396.

[7] Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. The Journal of Dermatology. 2012; 39: 145–150.

[8] Bradford J, Fischer G. Long-term management of vulval lichen sclerosus in adult women. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2010; 50: 148–152.

[9] Corazza M, Borghi A, Minghetti S, Toni G, Virgili A. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. Journal of the European Academy of Dermatology and Venereology. 2016; 30: 956–961.

[10] Trietsch MD, Nooij LS, Gaarenstroom KN, van Poelgeest MIE. Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature. Gynecologic Oncology. 2015; 136: 143–157.

[11] Tan A, Bieber AK, Stein JA, Pomeranz MK. Diagnosis and management of vulvar cancer: a review. Journal of the American Academy of Dermatology. 2019; 81: 1387–1396.

[12] Bleeker MCG, Visser PJ, Overbeek LIH, van Beurden M, Berkhof J. Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2016; 25: 1224–1230.

[13] Micheletti L, Preti M, Radici G, Boveri S, Di Pumpo O, Privitera SS, et al. Vulvar Lichen Sclerosus and Neoplastic Transformation: A Retrospective Study of 976 Cases. Journal of Lower Genital Tract Disease. 2016; 20: 180–183.

[14] Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E. Lichen sclerosus and risk of cancer. International Journal of Cancer. 2017; 140: 1998–2002.

[15] Corazza M, Borghi A, Gafà R, Ghirardi C, Ferretti S. Risk of vulvar carcinoma in women affected with lichen sclerosus: results of a cohort study. Journal Der Deutschen Dermatologischen Gesellschaft. 2019; 17: 1069–1071.


Submission Turnaround Time

Top